Novo chief on approval of prize asset: Probably the biggest achievement
The approval of Novo Nordisk’s GLP-1 analogue Ozempic is probably “the biggest” achievement for chief science officer (CSO) Mads Krogsgaard Thomsen during his 26 years in the Danish diabetes group. He is happy that the company now possesses the two best products of the drug class.
BY MARTIN HAVTORN PETERSEN
Since 1991, Mads Krogsgaard Thomsen has been a part of Novo Nordisk’s R&D department and since the millennium, he has been responsible for the whole unit and involved in a range of new drug approvals.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s R&D chief: Semaglutide wins out every time
For abonnenter
